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Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction caused by antibodies to the heparin/platelet 
factor 4 (PF4) complex, resulting in thrombocytopenia and prothrombotic state. HIT diagnosis is challenging and depends on clini-
cal presentation and laboratory tests. We investigated the usefulness of clinical scores and heparin/PF4 ELISA optical density (OD) 
as a diagnostic marker and thrombosis predictor in HIT.
Methods: We analyzed 92 patients with suspected HIT. The heparin/PF4 antibody was measured using a commercial ELISA kit (GTI, 
USA). For each patient, the 4 T’s score and Chong’s score were calculated.
Results: Of the 92 patients, 28 were anti-heparin/PF4-seropositive. The 4 T’s score and Chong’s score showed good correlation (r 
=0.874). The 4 T’s score and OD values showed good performance for diagnosis of the definite and unlikely HIT groups; however, 
OD levels showed better sensitivity (93.8%) than the 4 T’s score used alone (62.5%). Of the 92 patients, 26 developed thrombosis. 
The OD values were significantly higher in patients with thrombosis than in those without thrombosis (0.52 vs. 0.22, P<0.001). Pa-
tients with high OD values (OD>0.4) had an increased risk of thrombosis (adjusted odds ratio 9.44 [3.35–26.6], P<0.001) and a 
shorter 250-day thrombosis-free survival (32.1% vs. 54.7%, P=0.012).
Conclusions: ELISA OD values in combination with clinical scoring can improve the diagnosis of and thrombosis prediction in HIT. 
More attention should be paid to the use of clinical scores and OD values as thrombosis predictors in HIT.
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INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is a distinct 
clinicopathologic syndrome caused by platelet-activating 
antibodies that recognize heparin/platelet factor 4 (PF4) 
complexes. HIT is a potentially serious hypercoagulable 
state and is associated with a wide spectrum of venous and 
arterial thrombosis. The early recognition of HIT is critical 
because thrombotic complication can be life-threatening, 
and failure to discontinue heparin and initiate an alternative 
anticoagulant can result in increased morbidity and mortal-
ity [1]. The diagnosis of HIT is difficult and primarily relies 
on clinical criteria and serologic testing for heparin/PF4 an-
tibodies. Various scoring systems have been developed to 
estimate the probability of HIT based on clinical informa-
tion. These previously developed clinical scoring systems 
are useful only for retrospective analysis because these scores 
use criteria such as response to heparin withdrawal or re-
exposure to heparin, which limit their applicability for pro-
spective diagnosis [2]. Recently, Warkentin and Heddle [3] 
developed a new scoring system for the pretest probability 
of HIT, the 4 T’s scoring system (Table 1), which takes ad-
vantage of new information regarding the clinical features 
of HIT and is simple to apply prospectively. The 4 T’s scor-
ing system was demonstrated to be accurate when used in 
conjunction with the serotonin release assay (SRA), and a 
low score had a high negative predictive value [4]. Labora-2     www.kjlm.org
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tory documentation of HIT antibodies has been crucial in 
determining the clinical scope of HIT syndrome. The SRA 
is considered the gold standard for HIT diagnosis; however, 
the SRA cannot be performed in most clinical laboratories. 
Alternatively, the commercial heparin/PF4 ELISA, which 
detects heparin/PF4 antibodies, can be easily performed on 
standard platforms in clinical laboratories and is more widely 
available. The heparin/PF4 ELISA is known to be very sen-
sitive to the presence of anti-heparin/PF4 antibody [5]; how-
ever, it is less specific for the diagnosis of HIT, partly because 
it can also detect non-pathologic antibodies [6]. Not all pa-
tients with anti-heparin/PF4 antibodies develop HIT, and, 
conversely, the absence of detectable anti-heparin/PF4 does 
not completely exclude HIT [1]. Although the heparin/PF4 
ELISA is designed to report dichotomous results (positive/
negative), recent studies have shown that absolute optical 
density (OD) values have diagnostic and prognostic utility.
A previous study reported that increasing OD was associ-
ated with an increasing probability of HIT and that higher 
OD values were associated with an increasing risk of subse-
quent thrombosis in HIT [7]. We performed a retrospective 
review of all patients with suspected HIT who underwent 
heparin/PF4 ELISA at a tertiary care hospital. The aim of 
this study was to evaluate the clinical utility of clinical scor-
ing systems and the heparin/PF4 ELISA for diagnosing HIT 
and to investigate whether higher OD values correlate with 
a higher HIT pretest probability score and higher risk of 
thrombotic complication and mortality.
MATERIALS AND METHODS
1. Patients and methods
Ninety-two patients who were requested to undergo anti-
heparin/PF4 antibody test from October 2007 to July 2009 
were the subjects of the present study. The anti-heparin/PF4 
antibody level was measured using a commercial ELISA kit 
(PF4 Enhanced; GTI, Waukesha, WI, USA). Briefly, the 
solid-phase ELISA microwells provide immobilized PF4: 
polyvinyl sulfonate (PVS) complexes as a target for the de-
tection of antibodies, because antibodies associated with 
HIT recognize sites on platelets that are created when PF4 
is complexed with heparin or another linear polyanionic 
compound such as PVS. After ensuring the binding of anti-
bodies recognizing a site on PF4:PVS, the unbound anti-
bodies are washed away. An alkaline phosphatase labeled 
anti-human globulin reagent (anti-IgG/A/M) is added to 
the wells and incubated. The unbound anti-IgG/A/M is 
washed away, and the substrate p-nitrophenyl phosphate is 
added. After a 30 min incubation period, the reaction is 
stopped by a sodium hydroxide solution, and the OD at 405 
nm is measured in a spectrophotometer. A result was con-
sidered positive if the OD value was greater than 0.40, in 
accordance with both the manufacturer’s instructions and 
the FDA-approved cut-off value. All the procedures were 
performed according to the manufacturer’s guidelines. Then 
Table 1. The 4 T’s scoring system
Characteristics 2 points 1 point 0 point
Thrombocytopenia >50% platelet fall (nadir ≥ 20 × 10
9/L) 30–50% platelet fall or nadir 10–19 × 10
9/L <30% platelet fall or nadir ≤ 10 × 10
9/L
Timing of platelet count fall Clear onset between days 5–10 or ≤1 day 
  (if heparin exposure within past 30 days)
Consistent with days 5–10 fall, but not clear 
  (e.g., missing platelet counts) or ≤1 day 
  (heparin exposure within past 31–100 days)
Platelet count fall ≤4 days without recent 
  heparin exposure
Thrombosis or other sequelae New thrombosis; skin necrosis; acute systemic 
  reaction after intravenous heparin bolus
Progressive or recurrent thrombosis; 
  erythematous skin lesions; suspected 
  thrombosis (not yet proven)
None
Other cause of thrombocytopenia None evident Possible Definite
Pretest probability score: 6–8 = high; 4–5 = moderate; 0–3 = low. Modified from Greinacher and Warkentin [1].
Table 2. Chong’s scoring system
Criteria Point 
Onset of thrombocytopenia* (or a substantial decrease in platelets, 
   by >50% of baseline) 4–14 days after starting heparin
3
Onset of thrombocytopenia outside above time interval 1
Exclusion of other causes of thrombocytopenia 2
Thrombocytopenia resolves after stopping heparin 2
Thrombocytopenia recurs on heparin rechallenge 1
Thrombosis associated with thrombocytopenia 1
Laboratory tests
   Immunoassay positive 2
   Functional assays: two-point system 3
   Functional assays: non-two-point system 2
Modified from Chong and Chong [2].
* The presence of thrombocytopenia is mandatory. Thrombocytopenia is defined as a 
platelet count below 150 × 10
9/L. If the total point is >7, 5–6, 3–4, and <3, the 
diagnosis of HIT is considered definite, probable, possible, and unlikely, respectively.
Abbreviation: HIT, heparin-induced thrombocytopenia.Kim SY, et al.  •  Heparin-induced Thrombocytopenia
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data were reviewed from patients’ electronic clinical, labo-
ratory, and radiographic records from initial hospital visits 
and a follow-up period of up to 10 months. Using the 4 T’s 
score, the pre-test probability of HIT was retrospectively 
calculated for each patient on the basis of the clinical records 
at the time the test was ordered by one of the investigators 
(Table 1) [6]. Retrospective probability scores were calcu-
lated using Chong’s scoring system (Table 2) [2].
2. Statistical analysis
Data were compared using the Mann–Whitney U test 
and Kruskal–Wallis ANOVA for continuous variables and 
the chi-square test for categorical variables. The association 
of clinical scores and OD values was analyzed using Spear-
man’s correlation coefficient. Sensitivity and specificity were 
calculated for the heparin/PF4 ELISA and 4 T’s scoring sys-
tem for the definite and unlikely HIT groups by using Chong’s 
scoring system. Thrombosis-free survival and overall sur-
vival were estimated using the Kaplan–Meier method, and 
the difference between curves was determined by using the 
log-rank test. Heparin/PF4 ELISA OD level and 4 T’s score 
cut-offs for predicting thrombotic complication were deter-
mined using ROC curve analysis.
 
RESULTS
1. Patient characteristics
The median age was 69-yr-old (range, 1–92 yr), and 44 
patients (47.8%) were female (Table 3). A majority of pa-
tients had undergone cardiovascular surgery (62 [67.4%]) 
or were managed by internal medicine for underlying ma-
lignancy (17 [18.5%]). Forty-four patients (47.8%) had re-
Table 3. Characteristics of 92 patients who underwent the anti-heparin/PF4 antibody ELISA
Total (N = 92) Heparin/PF4 Ab+ (N = 28) Heparin/PF4 Ab– (N = 64) *P value
Age (yr) 69.1 (1.4–91.8) 71.5 (10.0–82.1) 68.4 (1.4–91.8) 0.717
Female sex (%) 44 (47.8) 16 (57.1) 28 (43.8) 0.264
Platelet count, nadir ( × 10
9/L) 29 (4–266) 24 (6–69) 33 (4–266) 0.053
% Decrease platelet count from baseline 81.4 (11.5–3.2) 88.2 (35.1–97.9) 78.8 (11.5–98.4) 0.019
Type of anticoagulation, N (%)
   UFH only 44 (47.8) 16 (57.1) 28 (43.8) 0.481
   UFH + LMWH 43 (46.7) 11 (39.3) 32 (50.0)
   LMWH only 5 (5.4) 1 (3.6) 4 (6.2)
Patient type, N (%)
   Cardiothoracic surgery 62 (67.4) 24 (85.7) 38 (59.4) 0.045
   General surgery 4 (4.3) 0 4 (6.2)
   Cardiac medical 9 (9.8) 0 9 (14.1)
   Other medical 17 (18.5) 4 (14.3) 13 (20.3)
OD value 0.256 (0.015–3.242) 0.665 (0.420–3.242) 0.207 (0.015–0.371) <0.001
4 T’s score 3 (0–8) 5 (0–8) 3 (0–6) <0.001
   Low probability 48 (52.2) 6 (21.4) 42 (65.6) <0.001
   Intermediate probability 33 (35.9) 13 (46.4) 20 (31.3)
   High probability 11 (11.9) 9 (32.1) 2 (3.1)
Chong’s score 3.5 (0–11) 7 (2–11) 3 (0–7) <0.001
   Unlikely HIT 29 (31.5) 1 (3.6) 28 (43.8) <0.001
   Possible HIT 28 (30.4) 4 (14.3) 24 (37.5)
   Probable HIT 19 (20.7) 8 (28.6) 11 (17.2)
   Definite HIT 16 (17.4) 15 (53.6) 1 (1.6)
Direct thrombin inhibitor therapy 14 (15.2) 8 (28.6) 6 (9.4) 0.018
Thromboembolic events 26 (28.3) 17 (60.7) 9 (14.1) <0.001
Mortality 41 (44.6) 10 (35.7) 31 (48.4) 0.259
*P value: chi-square test for categorical variables and Man-Whitney U test for continuous variables.
Data are shown as the median (range) for continuous variables or the number (percentage) for categorical variables unless otherwise indicated. Heparin/PF4 Ab was measured by a 
commercial ELISA kit, and positive results were defined as optical density (OD) value ≥ 0.4.
Abbreviations: PF4, platelet factor 4; Ab, antibody; UFH, unfractionated heparin; LMWH, low molecular weight heparin; OD, optical density; HIT, heparin-induced thrombocytopenia.4     www.kjlm.org
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ceived only unfractionated heparin (UFH), 43 (46.7%) both 
UFH and low molecular weight heparin (LMWH), and 5 
(5.4%) LM  WH only. Twenty-eight (30.4%) patients were 
identified as anti-heparin/PF4-seropositive. According to 
Chong’s scoring system, 16 (17.4%) of 92 patients were de-
fined as having definite HIT, 19 (20.7%) as having probable 
HIT, 28 (30.4%) as having possible HIT, and 29 (31.5%) as 
unlikely to have HIT. According to the 4 T’s scoring system, 
there were 11 patients (12.0%) with high pretest probability, 
33 (35.9%) with intermediate pretest probability, and 48 
(52.2%) with low pretest probability. There was good corre-
lation (Spearman correlation, r=0.874, P<0.001) between 4 
T’s scores and Chong’s scores. Heparin was discontinued 
for all patients after the clinical suspicion of HIT, regardless 
of the anti-heparin/PF4 test results. Fourteen patients un-
derwent further anticoagulation with direct thrombin in-
hibitors (11 patients with lepirudin, 2 patients with argatro-
ban, and 1 patient with both lepirudin and argatroban).
2.   Diagnostic performance of HIT scoring systems and 
heparin/PF4 antibody ELISA OD values
Heparin/PF4 antibody ELISA OD values according to 
HIT scoring systems are shown in Fig. 1. The OD was sig-
nificantly different between the 4 T’s category of high, inter-
mediate, and low probability (P<0.001). There was a signif-
icant difference between the categories of high versus low 
and intermediate (P<0.001, P=0.001, respectively: Dunn 
test) but not between the categories of intermediate and low 
(P=0.118). The OD was significantly different between 
Chong’s scoring category of definite, probable, possible, and 
unlikely for HIT (P<0.001). There was significant differ-
ence between the categories of definite vs. unlikely, definite 
vs. possible, and definite vs. probable (P<0.001) but not be-
tween the categories of probable vs. possible and possible 
vs. unlikely (P=1.0).
The diagnostic characteristics of the 4 T’s score and hepa-
rin/PF4 antibody test were compared with Chong’s scoring 
system (Table 4). Using the manufacturer’s threshold for a 
positive test at OD>0.4, only 1 patient was negative for 
heparin/PF4 antibody in the definite HIT group, and 1 pa-
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Fig. 1. Optical density (OD) values according to (A) the 4 T’s and (B) Chong’s scoring system. Bars represent median OD level. Uppermost P values were calculated 
using the Kruskal–Wallis test, and pairwise comparisons were performed using the Dunn test.
4 T’s score Chong’s score
Table 4. The 4 T’s score and heparin/PF4 ELISA positivity according to Chong’s category
Chong’s 
  category
N of pa-
tients OD > 0.4 4 T’s pretest 
probability
4 T’s High + OD 
> 0.4 
Definite 16 (17.4) 15/16 (93.8) High: 10/16 (62.5)
Low: 0/19 (0)
9/16 (56.3)
Probable 19 (20.7) 8/19 (42.1) High: 1/19 (5.3)
Low: 2/19 (10.5)
0/19 (0)
Possible 28 (30.4) 4/28 (14.3) High: 0/28 (0)
Low: 19/28 (67.7)
0/28 (0)
Unlikely 29 (31.5) 1/29 (3.5) High: 0/29 (0)
Low: 27/29 (93.1)
29/29 (100)
*Sensitivity 93.8%
†Sensitivity 62.5% Sensitivity 56.2%
Specificity 96.6%
‡Specificity 93.1% Specificity 100%
*Sensitivity and specificity were defined for the 45 patients in the Definite and Unlikely HIT cat-
egories by Chong’s scoring system; 
†Sensitivity of high pretest probability was defined for the 
patients in the Definite HIT category by Chong’s scoring system; 
‡Specificity of low pretest prob-
ability was defined for the patients in the Unlikely HIT category by Chong’s scoring system.
Data are shown as the number (percentage) unless otherwise indicated.
Abbreviations: PF4, platelet factor 4; OD, optical density.Kim SY, et al.  •  Heparin-induced Thrombocytopenia
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tient was positive for heparin/PF4 antibody in the unlikely 
HIT group. Therefore, considering the definite and unlikely 
HIT patients only, the sensitivity and specificity of the hepa-
rin/PF4 ELISA with an OD cut-off of 0.4 was 93.8% and 
96.6%, respectively. Ten among 11 patients with high pre-
test probability according to the 4 T’s score were classified 
as definite HIT by Chong’s scoring system. None of the pa-
tients with high pretest probability was assessed as unlikely 
HIT by Chong’s scoring system. Therefore, the heparin/PF4 
antibody test showed better sensitivity (93.8%) than the 4 
T’s score used alone (62.5%). When heparin/PF4 antibody 
was combined with 4 T’s high pretest probability, the speci-
ficity was 100%, but the sensitivity was only 56.3%.
3. Thrombosis and mortality
Thromboembolic events were observed in 26 patients 
(28.3%). In 17 patients (65.4%), arterial thrombosis occurred 
(6 had thrombosis involving peripheral arteries, 5 intra-atrial 
or intraventricular thrombi, 4 brain infarction, and 2 splenic 
infarction), and 9 patients developed venous thrombosis (4 
experienced new or progressive pulmonary embolism, 4 
peripheral venous stasis or venous gangrene, and 1 recur-
rent extracorporeal circuit thrombosis). The clinical and 
laboratory characteristics of all patients who experienced 
thromboembolic complications were summarized in Table 
5. Of the 26 patients, 17 patients (65.4%) tested positive for 
heparin/PF4 antibody (OD value>0.4), while 9 patients 
(34.6%) tested negative for heparin/PF4 antibody (OD≤ 
0.4). Thrombocytopenia was more severe in patients who 
developed thrombosis (platelet nadir 21×10
9/L, P=0.015). 
OD values were significantly higher in patients with throm-
bosis (median, 0.52), compared to those without thrombo-
sis (0.22, P<0.001). More patients in the 4 T’s category of 
intermediate or high pretest probability experienced throm-
boembolic complication (Table 5). As the OD value increa-
sed, the frequency of thromboembolic complication tended 
to increase (Fig. 2). When the OD cut-offs of 0.4 and 1.0 
were considered, 60.7% (17/28) patients with OD>0.4 sub-
sequently developed thromboembolic complications, while 
14.1% (9/64) of patients with OD≤0.4 developed thrombo-
sis. Among patients with OD>1.0, 77.8% (7/9) developed 
thrombosis, and 22.9% (19/83) of patients with OD≤1.0 
developed thrombosis. Thus, differences of the thrombosis 
risk between patients with OD>1.0 and those who with 
OD≤1.0 were greater, compared with differences between 
patients with OD>0.4 and those who with OD≤0.4. When 
the combination of OD values and 4 T’s scores were consid-
ered, among 22 patients with 4 T’s score ≥4 and OD>0.4, 
11 patients (68.2%) developed thrombosis, a higher fre-
quency than when 4 T’s score ≥4 alone (22/44, 50.0%), or 
OD>0.4 alone (17/28, 60.7%) were considered. Meanwhile, 
among 4 patients with 4 T’s score ≥6 (high probability) and 
OD>1.0, 3 patients (75.0%) developed thrombotic compli-
cation, the frequency for which was between 72.7% (8/11) 
when high probability patients were considered alone and 
77.8% (7/9) when patients with OD>1.0 considered alone. 
ROC curves were constructed to determine the best cut-
offs for the OD value and 4 T’s score for the prediction of 
thrombosis (Fig. 3). The OD value of 0.427 and 4 T’s score 
of 4 had the best performance as cut-off values. At the OD 
Table 5. Characteristics of patients with and without thromboembolic complication
Thrombosis
(N = 26)
No thrombosis
(N = 66)     P value*
Age (yr) 63.3 (10.0–83.8) 69.2 (1.4–91.8) 0.776
Female sex (%) 15 (57.7) 29 (43.9) 0.234
Platelet count, nadir 
   (×10
9/L)
21 (7–67) 33 (4–266) 0.015
% Decrease platelet count 
  from baseline
89.5 (48.5–97.9) 79.3 (11.5–98.4) 0.019
LMWH only 1 (3.9) 4 (6.1) 0.673
Cardiopulmonary bypass surgery 19 (73.1) 73 (65.2) 0.622
ELISA optical density 0.52 (0.11–2.81) 0.22 (0.02–3.24) <0.001
   OD>0.4  17 (65.4) 11 (16.7) <0.001
   OD>1.0  7 (26.9) 2 (3.0) 0.001
4 T’s score 5 (1–8) 3 (0–6) <0.001
   4 T’s score≥4 22 (84.6) 22 (33.3) <0.001
   4 T’s score≥6 8 (30.8) 3 (4.6) 0.001
Direct thrombin inhibitor therapy 8 (30.8) 6 (9.1) 0.009
*P value: chi-square test for categorical variables and Mann–Whitney U test for continuous 
variables.
Data are shown as the median (range) for continuous variables or the number (percentage) for 
categorical variables unless otherwise indicated.
Abbreviations: LMWH, low molecular weight heparin; OD, optical density.
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value of 0.427, the sensitivity to predict thrombosis was 
65.4%, and specificity was 88.4%.
We compared the overall survival and thrombosis-free 
survival for all the patients according to the OD cut-offs of 
0.4 and 1.0 (Fig. 4). Overall mortality of the patients was 
44.6%. The overall survivals (OS) were not different between 
patients with high OD values (OD>0.4 or OD>1.0) and 
patients with lower OD values (250-day OS rate for patients 
with OD>0.4 vs. OD≤0.4: 67.9% vs. 56.3%, P=0.246; OD 
>1.0 vs. OD≤1.0: 55.6% vs. 60.2, P=0.908). The 250-day 
thrombosis-free survival rate of patients with OD>0.4 was 
32.1%, and that of patients with OD≤0.4 was 54.7% (P= 
0.012) (Fig. 4A). The 250-day thrombosis-free survival rate 
of patients with OD>1.0 was also significantly lower than 
that of the patients with lower OD values (22.2% vs. 50.6%, 
P=0.003) (Fig. 4B).
Patients with OD>0.4 had increased risk of thrombosis, 
as shown by the odds ratio (OR) for thromboembolic events 
of 9.44 (95% confidence interval (CI), 3.35–26.6; P<0.001). 
The OR for patients with OD>1.0 was 11.79 (95% CI, 2.26– 
Fig. 3. ROC curve relating heparin/PF4 ELISA (A) optical density (OD) value and (B) 4 T’s scores to occurrence of thromboembolic complication. (A) When the OD 
cut-off is 0.427, the sensitivity is 65.4%, and the specificity is 88.4%. (B) When the 4 T’s score is greater than or equal to 4, the sensitivity is 69.2%, and the speci-
ficity is 84.8%.
Abbreviation: AUC, area under curve.
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61.55; P=0.003). When OD values >1.0 were compared 
with those with lower positive OD values between 0.4 and 
1.0, those with higher OD values tended to have increased 
risk; however, the increase was not statistically significant 
(OR, 3.85; 95% CI, 0.6–23.05; P=0.139). With multiple lo-
gistic regression analysis, higher OD value was an indepen-
dent predictor of thromboembolic event. The OR of pa-
tients with OD >0.4–after adjusting for age, gender, cardio-
vascular bypass, and baseline platelet count–was 10.01 (95% 
CI, 3.26–30.73; P<0.001), and the adjusted OR of patients 
with OD >1.0 was 12.10 (95% CI, 2.17–67.55; P=0.004). 
Overall, for every increase of 0.2 OD values in the heparin/
PF4 ELISA, the risk of the thromboembolic events increased 
by OR of 1.39 (95% CI, 1.09–1.78; P=0.007).
 
DISCUSSION
HIT is a serious complication of heparin treatment, which 
often leads to life-threatening thrombotic events. Although 
HIT is a relatively well-known complication, its diagnosis is 
still challenging because of its variable presentation and the 
difficulty of proving heparin’s effects in patients with many 
other risk factors [8]. The gold standard for HIT diagnosis 
is the SRA; however, because this test is technically difficult, 
time-consuming, and involves the use of radioactive mate-
rials, it is usually only performed by a few reference labora-
tories. Therefore, obtaining SRA results in a timely manner 
is almost impossible in real practice. Rapid diagnosis of HIT 
is critical, because timely discontinuation of heparin and 
use of alternative anticoagulants, such as direct thrombin 
inhibitors, is known to reduce both morbidity and mortal-
ity [8]. Recently, several reports have suggested the useful-
ness of the clinical pretest probability scoring system, the 4 
T’s score, in combination with the more rapid and simple 
enzyme-immunoassay (EIA) for heparin/PF4 antibodies to 
assess the probability of HIT [9, 10]. Patients with HIT typi-
cally have thrombocytopenia 5–10 days after exposure to 
heparin. HIT-IgG antibodies generally are not detectable 
before day 5 of heparin treatment, but are readily detectable 
using sensitive assays when the platelet count first begins to 
fall because of HIT. EIA for heparin/PF4 antibodies is known 
to be less specific because it detects all antibodies, including 
those that do not activate platelets. However, in combina-
tion with clinical scoring systems, interpretation of the test 
results could become more reliable [10, 11]. Although the 
turnaround time of the heparin/PF4 ELISA may vary de-
pending on the conditions of each laboratory, it can usually 
be performed far more rapidly and easily than the SRA. Fur-
thermore, another useful aspect of the EIA for heparin/PF4 
antibody is that the results can be interpreted quantitatively. 
Several reports have shown that higher OD values are re-
lated to either the higher diagnostic probability of HIT [12-
14] or the risk of thrombosis [7, 15]. Other studies have 
demonstrated that the greater the magnitude of a positive 
EIA, the greater the likelihood that the patient has heparin-
dependent platelet-activating antibodies and, hence, clinical 
HIT [6, 7, 14, 15]. Zwicker et al. [7] reported that the risk of 
thrombosis in patients with higher OD values (OD > 1.0) 
was approximately sixfold higher than that in patients with 
weak-positive results (0.4–1.0 OD units), and Warkentin et 
al. [14] found that strong-positive results of heparin/PF4 
ELISA were associated with stronger SRA results. The re-
sults of our study support the findings of previous studies in 
that patients with increasing OD values also had a greater 
risk of thromboembolic complication. Thrombotic events 
of the arterial system were more frequently observed in this 
study. Previous prospective studies on HIT showed that 
HIT patients with cardiovascular disease were more likely 
to develop arterial thrombosis, whereas venous and arterial 
thrombotic events occur in approximately equal numbers 
in medical patients, and venous thrombosis was strongly 
associated with the postoperative state [16]. The pattern of 
thrombosis in this study could be thought of as reflecting 
the characteristics of the study population, with its predom-
inance of cardiovascular surgery patients. In contrast to 
thrombosis risk, mortality did not differ according to the 
OD values. One possible explanation for this is that clini-
cians requested HIT testing for those patients with suspected 
HIT, with the result that most suspected patients underwent 
proper HIT management, namely discontinuation of hepa-
rin and administration of alternative anticoagulants. With 
the ROC analysis, the best cut-off for the prediction of throm-
bosis was an OD value of 0.427 and a 4 T’s score of 4. These 
are close to the currently used cut-offs of OD value 0.4 and 
4 T’s category of intermediate probability. This finding im-
plies that the current cut-offs can be used as predictors of 
thrombosis.
Our study had some limitations. First, it was a retrospec-
tive study, and hence, an exact assessment of the prevalence 
and incidence of HIT and its complications was not possi-
ble. Second, it was a single-center study of a tertiary univer-
sity hospital, and cardiovascular surgical patients were pre-
dominant; therefore, the study population did not reflect 
the characteristics of the entire Korean population. Finally, 
the gold standard laboratory test, the SRA, was not perform  ed; 
hence, interpretation of the data was limited.
This is the first report of the clinical and laboratory char-
acterization of HIT in the Korean population. Our results 8     www.kjlm.org
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were consistent with those of previous studies, and we were 
able to confirm the usefulness of the heparin/PF4 ELISA and 
the clinical scoring system for the diagnosis of and throm-
bosis prediction in HIT in Korean patients. More attention 
must be paid to the use of clinical scores and OD values as 
thrombosis predictors in HIT.
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